Vaccine Development using DoE and its Manufacturing Technology with the application of Advanced Data Analytics

Conjugate vaccine development is a complex, complicated and lengthy process comprising of multiple antigenic vaccine components. The Serum Institute of India, a global leader, employs advanced data analytics and Design of Experiments (DoE) principles to develop and optimize Vaccines R&D and manufacturing. By integrating tools like Advanced Data Analytics, we’ve significantly enhanced yield consistency and process robustness from the initial stage of development.

This presentation will explore how advanced analytics and smart manufacturing are revolutionizing our vaccine development and production approach. We’ll discuss addressing complex scientific challenges, scaling up early-stage data for commercial manufacturing, and leveraging real-time data analytics through high-performance online sensors.

I will also share insights into the application of Online Data Analytics platforms in establishing flexible QbD frameworks. Join us to discover how data-driven decision-making is driving impactful advancements in vaccine manufacturing using Predictive & Prescriptive analytics.

Presented by Dr. S.K. Jana, Director – R&D and Manufacturing, Human Vaccine Development, Serum Institute of India Pvt. Ltd.

Dr. S.K. Jana is a Ph. D. in Bio-Chemical Engineering, an M. Tech. in Bio-chemical Engineering, B. Tech. in Chemical Technology, B. Sc. in Chemistry & PGDOM (Post Graduate Diploma in Operations Management). Education is from highly reputed Calcutta University, Jadavpur University Kolkata & IIT, Delhi. Dr. Jana is having 30+ years of industrial experience in the fields of the Biopharmaceuticals & Vaccine industry, recombinant & non-recombinant Biosimilar product development from early stage, late stage development, pilot scale products development & commercial scale production for upstream & Downstream for microbial as well as Cell culture, Bio-analytic methods development, Polysaccharide-protein conjugate vaccine, Technology Transfer, Project planning & execution, extensive experience in process & Technology development, & Technology transfer with product delivery of Lovastatin, rh-G-CSF, Hepatitis-B vaccine (r-HBsAg), rh-IFN-α 2b, r-Streptokinase, rh-Insulin, r-Erythropoietin (CHO cell line), Hib conjugate, Penta valent & Cholera vaccines, Pneumococcal Polysaccharide Conjugate Vaccine with 16 patents & 17 publications.. Currently, as Director, he looks after R&D and Manufacturing of Human Vaccine Development related activities & other vaccines at Serum Institute of India Pvt Ltd., Pune, India.